Overview

A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This proof-of-concept study evaluates the clinical efficacy and safety of DCN01 in prepping of the periocular region.
Phase:
Phase 2
Details
Lead Sponsor:
Deacon Biosciences, Inc.
Collaborator:
ORA, Inc.
Treatments:
Anti-Infective Agents